Imagine a world where developing new medicines is faster, cheaper, and less reliant on the use of animals for testing. Novel multi-organ in vitro
Organ-on-a-chip adoption: The roadmap to broader use
Paving the way for Organ-on-a-chip adoption Drug discovery is becoming more complex as we move from a small molecule world to large molecules and
CN Bio appoints Lydia Seymour as VP People and Culture to further strengthen leadership team
Key appointment to support continued UK and US team expansion CN Bio, a leading provider of single- and multi-organ microphysiological systems,
Global Fatty Liver Day 2024: How Organ-on-a-Chip Addresses R&D Challenges
To commemorate Global Fatty Liver Day on June 13, this article explores how organ-on-a-chip models are transforming liver disease research. Over
Meet the CN Bio team -Dr. Dharaminder Singh
Welcome to our new "Meet the team" blog series, where you'll get a behind-the-scenes look at the incredible individuals who make our company
CN Bio raises $21 million USD in first close of Series B investment round
Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively. Investment will expand product
Understanding the mechanism of toxicity: OOC’s crucial role
It’s commonly acknowledged that the current drug discovery process is inefficient with large numbers of drugs failing in the clinic. Almost a third
CN Bio selected for NC3R’s SensOoChip Challenge to develop advanced Heart-on-a-Chip
Part of the wider CRACK IT scheme – the multi-challenge competition aims to leverage CN Bio's existing OOC expertise - our MPS development and
CN Bio appoints Joseph Parisi as US Director of Sales
CN Bio appoints Joseph Parisi as US Director of Sales to support accelerated growth in key OOC market CN Bio, a leading Organ-on-a-Chip (OOC)